Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z8KS
|
|||
| Former ID |
DNCL002222
|
|||
| Drug Name |
Zanolimumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 3 | [1] | |
| Company |
Emergent BioSolutions
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00127881) Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.